Dermatology · Chicago, IL
NPI
1245672393
Since 2013
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
5841 S Maryland Ave
Chicago, IL, 60637
Phone (888) 824-0200
Groups this clinician bills Medicare through
Medicare paid, 2024
$85K
1,890 services
Medicare patients, 2024
829
Average age 74
Drug cost, 2024
$952K
292 prescriptions
Company payments, 2025
$481
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Oluwakemi Onajin was code 88305 (surgical pathology examination), 618 times for 359 patients. In total Oluwakemi Onajin billed 1,890 services in 46 codes, and Medicare paid $85K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-10-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 88305 Surgical Pathology Examination | Office | 618 | 359 | $58.59 | $36K |
| 88305 Surgical Pathology Examination | Facility | 471 | 312 | $30.17 | $14K |
| 17003 Destruction Skin Lesion | Facility | 131 | 16 | $1.58 | $207 |
| 99214 Office E&M - Established | Facility | 87 | 70 | $76.15 | $6,625 |
| 88341 Immunohistochemistry | Facility | 68 | 18 | $23.21 | $1,578 |
| 99213 Office E&M - Established | Facility | 61 | 51 | $52.03 | $3,174 |
| 88350 Immunohistochemistry | Facility | 51 | 13 | $24.20 | $1,234 |
| 88342 Immunohistochemistry | Facility | 45 | 40 | $29.03 | $1,306 |
| 88342 Immunohistochemistry | Office | 37 | 36 | $91.73 | $3,394 |
| 17000 Destruction Skin Lesion | Facility | 31 | 21 | $40.70 | $1,262 |
| 88312 Surgical Pathology Examination | Facility | 30 | 16 | $22.20 | $666 |
| 88341 Immunohistochemistry | Office | 22 | 16 | $78.34 | $1,724 |
| 11102 Skin Biopsy | Facility | 21 | 17 | $23.48 | $493 |
| 88304 Surgical Pathology Examination | Facility | 17 | 17 | $9.13 | $155 |
| 17110 Destruction Skin Lesion | Facility | 17 | 13 | $54.13 | $920 |
By year: 2022 $78K for 1,534 services; 2023 $83K for 1,680 services; 2024 $85K for 1,890 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88305 Surgical Pathology Examination | 618 | 359 | $58.59 | $36K |
| 88305 Surgical Pathology Examination | 471 | 312 | $30.17 | $14K |
| 88341 Immunohistochemistry | 68 | 18 | $23.21 | $1,578 |
| 88350 Immunohistochemistry | 51 | 13 | $24.20 | $1,234 |
| 88342 Immunohistochemistry | 45 | 40 | $29.03 | $1,306 |
| 88342 Immunohistochemistry | 37 | 36 | $91.73 | $3,394 |
| 88312 Surgical Pathology Examination | 30 | 16 | $22.20 | $666 |
| 88341 Immunohistochemistry | 22 | 16 | $78.34 | $1,724 |
| 88346 Immunohistochemistry | 17 | 16 | $29.88 | $508 |
| 88304 Surgical Pathology Examination | 17 | 17 | $9.13 | $155 |
Medicare prescription drug claims, 2024
In 2024, the drug Oluwakemi Onajin prescribed most often to Medicare patients was Cosentyx Unoready Pen (Secukinumab), with 34 prescriptions and refills. In total Oluwakemi Onajin wrote 292 Medicare prescriptions that cost $952K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Cosentyx Unoready Pen Secukinumab | 34 | 34 | Under 11 | $437K |
| Triamcinolone Acetonide Generic | 22 | 22 | 14 | $206 |
| Ketoconazole Generic | 22 | 22 | 13 | $299 |
| Doxycycline Hyclate Generic | 17 | 31 | 13 | $399 |
| Clobetasol Propionate Generic | 14 | 14 | Under 11 | $637 |
| Dupixent Syringe Dupilumab | 12 | 12 | Under 11 | $31K |
| Mometasone Furoate Generic | 11 | 11 | Under 11 | $155 |
| Inflectra Infliximab-Dyyb | 11 | 11 | Under 11 | $193K |
Brand drugs: - claims; generic drugs: 199 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Oluwakemi Onajin $481 ($481 in general payments such as food, travel and fees) from 2 companies. The largest payer was AstraZeneca UK Limited with $384.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.